How I classify #AML in 2023 😱 WHO & ICC 👉diagnosis (AML entities) ELN 👉 prognosis (fav vs. int/adverse) #cytology + #mutations + #cytogenetics 🔬🧬

Read the cell, guess the genetics. #HemePath #Genetics #leusm #AMLsm 🔬🧬🩸

Tips de rentrée > 🩸 Les bases du diagnostic de leucémie aiguë : 🔬 un laboratoire compétent 🤓 un cytologiste de qualité #Leucémie #Hématologie #Diagnostic

#CHIP Drives Increased Mortality Unaltered by CAD Interventions | ASH Clinical News | American Society of Hematology

Under-48-hour #RapidNGS is turning “wait a week” into “treat today.” ⚡️🧬 Same run → DNA RNA, on-the-spot FLT3/IDH calls, real-time #myeloMATCH trial slots, and a fighting chance for aggressive AML.Precision moves fast—so must we.happening at Fortis!!!! @RahulDoc2 @nikhil91sjmc

LS arises rapidly after immune-targeted therapy, highlighting the importance of enhanced methods of detection and treatment. https://t.co/5IFpnpJVbv #immunobiologyandimmunotherapy #lymphoidneoplasia

🚨 Just published! 🧬 The #genomic landscape of #AML: redefining classifications, ontogeny, and therapeutic strategies 👉 Download here: https://t.co/zL99OiH9Wy #leusm #AMLsm #Genomics #Hematology

Download link available until August 26, 2025

🚨 Just published! 🧬 The #genomic landscape of #AML: redefining classifications, ontogeny, and therapeutic strategies 👉 Download here: https://t.co/zL99OiH9Wy #leusm #AMLsm #Genomics #Hematology

What a wonderful end of the ISTH2024 by appearing in the highlights! #ISTH2025 @isth @Team2_U1011

Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults 👉enriched in NPM1 (FLT3wt) and UBTF mutations. 🔬🧬Morphology guides, but mutations define the diagnosis of AML. #leusm #AMLsm @LaureneFenwarth @benjamin_podvin https://t.co/Hex9tE2aT9

🩸 IDH1/2 mutations in intensively treated #AML: ➡️ NPM1 & DNMT3A co-mutations drive prognosis. ➡️ IDH1/2 persistence in remission does not predict progression. #leusm #AMLsm 🎉⁦@LaureneFenwarth⁩

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia @BloodCancerJnl https://t.co/ZIxQaEIXML

Very happy to share our work on therapy-related myeloid neoplasms (t-MN) post-CD19 CAR T-cell therapy, published in @LeukemiaJnl and involving 4 French centers (@CHU_Lille, Lyon, Caen, St-Étienne). 🔗 https://t.co/lVrcI9P1B7 #CAR_T #Lymphoma #tMN #Hematology

Service note📢: Higher sensitivity doesn’t mean better test BUT it changes the question you can ask. 🔬 MRD-POS vs MRD-NEG isn’t enough to use #MRD to guide therapy (e.g., recommend or avoid HSCT). It's all about the threshold. #leusm #AMLsm

PFMG2025–integrating genomic medicine into the national healthcare sys...

#HappyNewYear2025 #Hematology Proud of our team at @CHU_Lille , dedicated to the molecular biology of hematological malignancies, who gave their best throughout 2024. THANKS to all of you! 🙌 Ready to take on new challenges in 2025!

Previous studies have shown self-reported Black patients have inferior treatment and survival outcomes compared to White patients, but why? Our work indicating that underlying genetics influence AML biology is now live at @NatureGen! 🎉🎈🍾

📍ELN 2017/2022 prognostic classifiers did not adequately stratify OS outcomes for #AMLsm patients treated with VEN-based regimens. 📍A 4-gene prognostic model (TP53, FLT3-ITD, NRAS, and KRAS) stratified OS outcomes with VEN-AZA treatment in #AMLsm. https://t.co/MOhsy4d6bk

ELN-risk classification for #AMLsm patients receiving less-intensive therapies (ELN 2024 Less-Intensive) https://t.co/CJKiQGCicE

Les patriarches hospitalo-U qui ne jurent que par leur H-index sont le cancer de la profession : Lettre hallucinante de l'ANPGM qui demande à ce que la loi ne soit pas appliquée car des personnes sans le diplôme veulent apparaître sur les compte rendus !!